(NYSEMKT: NRXS) Neuraxis's forecast annual revenue growth rate of 100.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.9%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.13%.
Neuraxis's revenue in 2026 is $4,281,510.On average, 4 Wall Street analysts forecast NRXS's revenue for 2026 to be $121,268,094, with the lowest NRXS revenue forecast at $109,230,452, and the highest NRXS revenue forecast at $132,636,978. On average, 3 Wall Street analysts forecast NRXS's revenue for 2027 to be $261,484,327, with the lowest NRXS revenue forecast at $251,230,040, and the highest NRXS revenue forecast at $269,175,043.
In 2027, NRXS is forecast to generate $261,484,327 in revenue, with the lowest revenue forecast at $251,230,040 and the highest revenue forecast at $269,175,043.